Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 494 clinical trials
Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT

This single arm, prospective study on the feasibility of a bridging treatment with low-dose azacitidine (AZA) in combination with short term CAG derived regimen prior to allogeneic stem cell transplantation (allo-HSCT) in patients with advanced myelodysplastic syndromes (MDS) .

allogeneic hematopoietic stem cell transplant
myelodysplastic syndromes
cell transplantation
cag protocol
myelodysplastic syndrome
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

This is a non-randomized, open-label, multi-site, single-dose, Phase 3 study in approximately 35 adults and pediatric subjects 2 and 50 years of age with sickle cell disease (SCD). The study will evaluate hematopoietic stem cell (HSC) transplantation (HSCT) with LentiGlobin BB305 Drug Product for SCD.

analgesia
priapism
karnofsky performance status
gene therapy
pediatric
  • 0 views
  • 16 Feb, 2024
  • 2 locations
Low Dose Treosulfan Based Conditioning Regimen in HSCT for Nijmegen Breakage Syndrome

The aim of the current study is to evaluate the safety and efficacy of low dose treosulfan based conditioning regimen in HSCT in Nijmegen breakage syndrome

  • 0 views
  • 05 Aug, 2020
Flu-Bu-Mel Conditioning Regimen for Myeloid Disease

For patients with acute myeloid leukemia (AML) or myelodyspasia syndrome undergoing allo-HSCT, the conditioning regimen will be 5-day Fludarabine, 2-day Busulifan and 2-day melphalan

  • 0 views
  • 16 Feb, 2024
  • 2 locations
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults

The purpose of the CliniMACS TCR-Biotin System and CliniMACS CD19 is to improve the safety and efficacy of allogeneic HLA-partially matched related or unrelated donors HSCT when no matched donors are available, to treat malignant and nonmalignant disorders for which HSCT is the recommended best available therapy.

immunosuppression
ejection fraction
renal function
graft versus host disease
congestive heart failure
  • 0 views
  • 16 Feb, 2024
  • 1 location
Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD

Therapy of severe intestinal graft-versus-host disease (GVHD) despite the introduction of novel target agents is associated with worse outcome compared to the other forms. Response to steroids is observed only in about 10% of patients. The most promising approaches are JAK inhibition and fecal microbiota transplantation. In this pilot study …

graft versus host disease
ruxolitinib
acute graft-versus-host disease
  • 0 views
  • 16 Feb, 2024
  • 1 location
Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag

Background Diamond-Blackfan anemia (DBA) is treated with steroids. But some people cannot take steroids, or steroids don t work. Other patients must get blood transfusions regularly which are time consuming and can have significant side effects. The drug eltrombopag can increase red blood cells. Researchers want to see if it …

blood cell count
cell counts
electrocardiogram
bone marrow erythroid
bone marrow biopsy
  • 0 views
  • 16 Feb, 2024
  • 1 location
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R or Chronic Myelomonocytic Leukemia-2 (CMML-2)

This is a Phase III multi-center, randomized, two-arm parallel-group, double-blind, placebo-controlled study of MBG453 or placebo added to azacitidine in adult subjects with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) who have an indication for treatment with azacitidine in first-line …

myelomonocytic leukemia
high risk myelodysplastic syndrome
cell transplantation
cmml-2
myelodysplastic syndrome
  • 0 views
  • 16 Feb, 2024
  • 23 locations
T Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse

Safety and Effectiveness of Donor T Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

  • 0 views
  • 05 Aug, 2020
Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients

The purpose of this study is to evaluate the efficacy and safety of decitabine combined with HAAG regimen in the treatment of newly diagnosed patients with ETP-ALL/LBL, T/M-MPAL and ALL/LBL with myeloid or stem cell markers.

  • 0 views
  • 16 Feb, 2024
  • 1 location